Literature DB >> 19557869

Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid.

Gregory P Owens1, Jeffrey L Bennett, Hans Lassmann, Kevin C O'Connor, Alanna M Ritchie, Andrew Shearer, Chiwah Lam, Xiaoli Yu, Marius Birlea, Cecily DuPree, R Anthony Williamson, David A Hafler, Mark P Burgoon, Don Gilden.   

Abstract

OBJECTIVE: Intrathecal IgG synthesis, persistence of bands of oligoclonal IgG, and memory B-cell clonal expansion are well-characterized features of the humoral response in multiple sclerosis (MS). Nevertheless, the target antigen of this response remains enigmatic.
METHODS: We produced 53 different human IgG1 monoclonal recombinant antibodies (rAbs) by coexpressing paired heavy- and light-chain variable region sequences of 51 plasma cell clones and 2 B-lymphocyte clones from MS cerebrospinal fluid in human tissue culture cells. Chimeric control rAbs were generated from anti-myelin hybridomas in which murine variable region sequences were fused to human constant region sequences. Purified rAbs were exhaustively assayed for reactivity against myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein by immunostaining of transfected cells expressing individual myelin proteins, by protein immunoblotting, and by immunostaining of human brain tissue sections.
RESULTS: Whereas humanized control rAbs derived from anti-myelin hybridomas and anti-myelin monoclonal antibodies readily detected myelin antigens in multiple immunoassays, none of the rAbs derived from MS cerebrospinal fluid displayed immunoreactivity to the three myelin antigens tested. Immunocytochemical analysis of tissue sections from MS and control brain demonstrated only weak staining with a few rAbs against nuclei or cytoplasmic granules in neurons, glia, and inflammatory cells.
INTERPRETATION: The oligoclonal B-cell response in MS cerebrospinal fluid is not targeted to the well-characterized myelin antigens myelin basic protein, proteolipid protein, or myelin oligodendrocyte glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19557869      PMCID: PMC2843543          DOI: 10.1002/ana.21641

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  50 in total

1.  Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?

Authors:  Christina Marik; Paul A Felts; Jan Bauer; Hans Lassmann; Kenneth J Smith
Journal:  Brain       Date:  2007-11       Impact factor: 13.501

2.  VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis.

Authors:  Gregory P Owens; Kimberly M Winges; Alanna M Ritchie; Sydni Edwards; Mark P Burgoon; Laura Lehnhoff; Kirsten Nielsen; John Corboy; Donald H Gilden; Jeffrey L Bennett
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

3.  Identification of autoantibodies associated with myelin damage in multiple sclerosis.

Authors:  C P Genain; B Cannella; S L Hauser; C S Raine
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

4.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

5.  Homogeneity of active demyelinating lesions in established multiple sclerosis.

Authors:  Esther C W Breij; Bianca P Brink; Rob Veerhuis; Christa van den Berg; Rianka Vloet; Riqiang Yan; Christine D Dijkstra; Paul van der Valk; Lars Bö
Journal:  Ann Neurol       Date:  2008-01       Impact factor: 10.422

6.  Varicella zoster virus is not a disease-relevant antigen in multiple sclerosis.

Authors:  Mark P Burgoon; Randall J Cohrs; Jeffrey L Bennett; Sarah W Anderson; Alanna M Ritchie; Sabine Cepok; Bernhard Hemmer; Don Gilden; Gregory P Owens
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

7.  Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis.

Authors:  Julio Sotelo; Adolfo Martínez-Palomo; Graciela Ordoñez; Benjamin Pineda
Journal:  Ann Neurol       Date:  2008-03       Impact factor: 10.422

8.  Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination.

Authors:  Shalina S Ousman; Beren H Tomooka; Johannes M van Noort; Eric F Wawrousek; Kevin C O'Connor; David A Hafler; Raymond A Sobel; William H Robinson; Lawrence Steinman
Journal:  Nature       Date:  2007-06-13       Impact factor: 49.962

9.  Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain.

Authors:  Barbara Serafini; Barbara Rosicarelli; Diego Franciotta; Roberta Magliozzi; Richard Reynolds; Paola Cinque; Laura Andreoni; Pankaj Trivedi; Marco Salvetti; Alberto Faggioni; Francesca Aloisi
Journal:  J Exp Med       Date:  2007-11-05       Impact factor: 14.307

10.  Neurofascin as a novel target for autoantibody-mediated axonal injury.

Authors:  Emily K Mathey; Tobias Derfuss; Maria K Storch; Kieran R Williams; Kimberly Hales; David R Woolley; Abdulmonem Al-Hayani; Stephen N Davies; Matthew N Rasband; Tomas Olsson; Anja Moldenhauer; Sviataslau Velhin; Reinhard Hohlfeld; Edgar Meinl; Christopher Linington
Journal:  J Exp Med       Date:  2007-09-10       Impact factor: 14.307

View more
  79 in total

1.  Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time.

Authors:  Xiaoli Yu; Mark Burgoon; Miyoko Green; Olga Barmina; Kathryn Dennison; Tiffany Pointon; Molly Davis; Don Gilden
Journal:  J Neuroimmunol       Date:  2011-11-12       Impact factor: 3.478

Review 2.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

3.  Antigen microarrays identify CNS-produced autoantibodies in RRMS.

Authors:  F J Quintana; M F Farez; G Izquierdo; M Lucas; I R Cohen; H L Weiner
Journal:  Neurology       Date:  2012-01-18       Impact factor: 9.910

4.  [Retrovirus superantigen hypothesis of multiple sclerosis].

Authors:  A Emmer; M S Staege; M E Kornhuber
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

5.  Multiple sclerosis: oligoclonal bands still yield clues about multiple sclerosis.

Authors:  Anne H Cross; Gregory F Wu
Journal:  Nat Rev Neurol       Date:  2010-11       Impact factor: 42.937

6.  Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Authors:  Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson
Journal:  Acta Neuropathol       Date:  2016-10-11       Impact factor: 17.088

Review 7.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Authors:  Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

8.  Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants.

Authors:  Kevin Blauth; John Soltys; Adeline Matschulat; Cory R Reiter; Alanna Ritchie; Nicholas L Baird; Jeffrey L Bennett; Gregory P Owens
Journal:  Acta Neuropathol       Date:  2015-10-28       Impact factor: 17.088

9.  Isolation of human monoclonal autoantibodies derived from pancreatic lymph node and peripheral blood B cells of islet autoantibody-positive patients.

Authors:  Mara Catani; Denise Walther; Michael R Christie; Kerry A McLaughlin; Ezio Bonifacio; Anne Eugster
Journal:  Diabetologia       Date:  2016-02       Impact factor: 10.122

10.  Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection.

Authors:  Marius Birlea; Gregory P Owens; Emily M Eshleman; Alanna Ritchie; Igor Traktinskiy; Nathan Bos; Scott Seitz; Yevgeniy Azarkh; Ravi Mahalingam; Don Gilden; Randall J Cohrs
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.